Michelle’s team is focused on developing and translating innovative ways of providing the best possible care from the time of diagnosis, through treatment and beyond to people with rare neurological conditions, including neuromuscular, neurodegenerative and genetic diseases. The research program also integrates interdisciplinary genomics research, together with community and consumer involvement.

The team is involved in clinical trials investigating potential drug treatments, coupled with studies to define biomarkers to monitor therapeutic effect and genomics in newborn screening.